glp-1 digital health news Novo Nordisk seeks partners to boost GLP-1RA weight loss outcomes Telehealth booms as demand for

November 2025: FDA approved expanded Zepbound (tirzepatide) indication for moderate-to-severe obstructive sleep apnea in adults with obesity, following SURMOUNT-OSA trial data showing 62.8% reduction in apnea-hypopnea index the first drug approval for sleep apnea treatment

see GLP-1 and hair loss: causes and prevention

Members who engage with Nooms GLP-1 Companion achieve 10% weight loss by month 4 at twice the rate compared to those who are not engaged

Conclusion GLP-1 agonists like tirzepatide are groundbreaking medications offering multiple health benefits

A systematic review of meta-analyses that evaluate risk factors for dementia to evaluate the quantity, quality, and global representativeness of evidence

46 GIPR is expressed in monocytes that infiltrate vessel walls and differentiate into macrophages and form cells as a component of the atherosclerosis plaque